Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
This study is being done to answer the following questions:
1. Does nivolumab in combination with standard chemotherapy work better for treating bladder cancer that has invaded the muscle layer of the bladder?
2. Can we identify a person’s response to treatment with chemotherapy plus nivolumab without needing the bladder removed surgically?
Muscle-invasive bladder cancer with selective bladder sparing
1. Age ≥ 18 years at the time of consent
2. Confirmed urothelial cancer of the bladder
3. Eligible for cystectomy
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive study drug for up to 3 months at which time your tumor will be assessed. If you are eligible, you may receive additional study drug for up to 4 months.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Sponsor-Investigator - Dr. Galsky (Funded by Bristol-Myers Squibb). He works at the Tisch Cancer Institute.